1. Home
  2. APPS vs EDIT Comparison

APPS vs EDIT Comparison

Compare APPS & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APPS
  • EDIT
  • Stock Information
  • Founded
  • APPS 2007
  • EDIT 2013
  • Country
  • APPS United States
  • EDIT United States
  • Employees
  • APPS N/A
  • EDIT N/A
  • Industry
  • APPS Multi-Sector Companies
  • EDIT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • APPS Miscellaneous
  • EDIT Health Care
  • Exchange
  • APPS Nasdaq
  • EDIT Nasdaq
  • Market Cap
  • APPS 153.5M
  • EDIT 176.7M
  • IPO Year
  • APPS N/A
  • EDIT 2016
  • Fundamental
  • Price
  • APPS $1.46
  • EDIT $1.52
  • Analyst Decision
  • APPS Hold
  • EDIT Buy
  • Analyst Count
  • APPS 4
  • EDIT 14
  • Target Price
  • APPS $2.38
  • EDIT $8.08
  • AVG Volume (30 Days)
  • APPS 2.6M
  • EDIT 3.1M
  • Earning Date
  • APPS 02-05-2025
  • EDIT 11-04-2024
  • Dividend Yield
  • APPS N/A
  • EDIT N/A
  • EPS Growth
  • APPS N/A
  • EDIT N/A
  • EPS
  • APPS N/A
  • EDIT N/A
  • Revenue
  • APPS $491,574,000.00
  • EDIT $61,759,000.00
  • Revenue This Year
  • APPS N/A
  • EDIT N/A
  • Revenue Next Year
  • APPS $9.20
  • EDIT N/A
  • P/E Ratio
  • APPS N/A
  • EDIT N/A
  • Revenue Growth
  • APPS N/A
  • EDIT 150.95
  • 52 Week Low
  • APPS $1.18
  • EDIT $1.39
  • 52 Week High
  • APPS $7.33
  • EDIT $11.58
  • Technical
  • Relative Strength Index (RSI)
  • APPS 38.12
  • EDIT 27.22
  • Support Level
  • APPS $1.40
  • EDIT $1.39
  • Resistance Level
  • APPS $1.48
  • EDIT $2.37
  • Average True Range (ATR)
  • APPS 0.09
  • EDIT 0.17
  • MACD
  • APPS 0.06
  • EDIT -0.04
  • Stochastic Oscillator
  • APPS 25.00
  • EDIT 13.24

About APPS Digital Turbine Inc.

Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: